GSK (GSK) to Release Quarterly Earnings on Wednesday

GSK (NYSE:GSK) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of $1.12 per share and revenue of $7.92 billion for the quarter. GSK has set its FY 2025 guidance at 4.250-4.590 EPS.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.05. The firm had revenue of $10.06 billion during the quarter, compared to analysts’ expectations of $7.52 billion. GSK had a net margin of 9.89% and a return on equity of 48.82%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.43 EPS. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

GSK Trading Down 1.3%

GSK opened at $37.49 on Tuesday. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $76.54 billion, a PE ratio of 19.32, a PEG ratio of 1.55 and a beta of 0.50. GSK has a 1-year low of $31.72 and a 1-year high of $44.67. The firm has a 50-day moving average price of $39.02 and a two-hundred day moving average price of $37.59.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, July 10th. Stockholders of record on Friday, May 16th were given a dividend of $0.4216 per share. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date was Friday, May 16th. This represents a $1.69 annualized dividend and a dividend yield of 4.50%. GSK’s payout ratio is currently 88.14%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Brighton Jones LLC bought a new position in GSK during the 4th quarter worth approximately $528,000. AQR Capital Management LLC boosted its stake in GSK by 84.4% during the 1st quarter. AQR Capital Management LLC now owns 40,239 shares of the pharmaceutical company’s stock worth $1,559,000 after acquiring an additional 18,420 shares during the last quarter. Finally, Empowered Funds LLC boosted its stake in GSK by 2.1% during the 1st quarter. Empowered Funds LLC now owns 79,174 shares of the pharmaceutical company’s stock worth $3,067,000 after acquiring an additional 1,598 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on GSK shares. Wall Street Zen cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Saturday. Berenberg Bank reiterated a “hold” rating on shares of GSK in a research report on Tuesday, June 3rd. Hsbc Global Res upgraded shares of GSK to a “strong sell” rating in a research report on Monday, April 28th. Finally, BNP Paribas started coverage on shares of GSK in a research report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 price target for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.